The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
NCT04828993
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Transthyretin Amyloid Polyneuropathy (ATTR-PN)
Interventions
DRUG:
tafamidis meglumine
Sponsor
Pfizer